Jagsonpal Pharmaceuticals Ltd. AI Stock Analysis
Want to see IN:JAGSNPHARM full AI Analyst Report?
Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) AI Stock Analysis
Jagsonpal Pharmaceuticals Ltd.
(NSE:JAGSNPHARM)
Strong financial fundamentals are the primary support for the score, led by the conservative balance sheet and solid cash generation. This is offset by weak technical momentum and a relatively high P/E ratio despite the modest dividend yield.
Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 11.37B
- Dividend Yield
- 1.91%
- Average Volume (3M)
- 12.57K
- Price to Earnings (P/E)
- 30.7
- Beta (1Y)
- 0.75
- Revenue Growth
- 11.71%
- EPS Growth
- -26.92%
- Country
- India
- Employees
- 1,297
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Jagsonpal Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Jagsonpal Pharmaceuticals Limited, an Indian company founded in 1964 and based in New Delhi, specializes in the development and manufacturing of both bulk active pharmaceutical ingredients and diverse medicinal formulations. Its product portfolio spa...
How the Company Makes Money
Jagsonpal Pharmaceuticals primarily makes money by selling pharmaceutical formulations (finished dosage medicines) in the Indian market. Revenue is generated through (1) domestic sales of branded formulations to channel partners such as stockists/dis...
Jagsonpal Pharmaceuticals Ltd. Financial Statement Overview
Summary
Strong profitability, a conservative balance sheet, and consistently positive cash flow support a robust financial profile. Growth, margins, returns, and operating cash flow have moderated or shown volatility recently.
Income Statement
78PositiveBalance Sheet
85Very PositiveCash Flow
82Very Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.16B | 2.87B | 2.69B | 2.09B | 2.37B | 2.18B |
| Gross Profit | 1.45B | 1.83B | 1.72B | 652.59M | 1.44B | 1.28B |
| EBITDA | 656.32M | 679.90M | 510.71M | 323.46M | 362.61M | 284.29M |
| Net Income | 451.90M | 430.82M | 553.61M | 224.63M | 267.21M | 188.55M |
Balance Sheet | ||||||
| Total Assets | 3.18B | 3.17B | 2.78B | 2.17B | 1.95B | 1.68B |
| Cash, Cash Equivalents and Short-Term Investments | 1.15B | 1.06B | 1.29B | 1.48B | 1.15B | 472.77M |
| Total Debt | 92.16M | 81.65M | 92.39M | 89.41M | 60.01M | 52.47M |
| Total Liabilities | 739.81M | 405.05M | 383.10M | 296.76M | 360.56M | 375.99M |
| Stockholders Equity | 2.41B | 2.76B | 2.40B | 1.87B | 1.59B | 1.31B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 466.64M | 549.52M | 349.18M | 463.37M | 51.31M |
| Operating Cash Flow | 0 | 468.12M | 553.00M | 351.66M | 466.54M | 55.98M |
| Investing Cash Flow | 0 | -356.49M | -451.47M | -245.48M | -576.71M | -257.79M |
| Financing Cash Flow | 0 | -121.49M | -116.98M | -89.11M | -4.57M | -175.52M |
Jagsonpal Pharmaceuticals Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JAGSNPHARM, the sentiment is Negative. The current price of 209.70 is below the 20-day moving average (MA) of 217.24, below the 50-day MA of 225.31, and above the 200-day MA of 207.85, indicating a neutral trend. The MACD of -3.47 indicates Positive momentum. The RSI at 37.23 is Neutral, neither overbought nor oversold. The STOCH value of 4.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JAGSNPHARM.
Jagsonpal Pharmaceuticals Ltd. Peers Comparison
Overall Rating
IN:SYNCOMF79Outperform
IN:VENUSREM74Outperform
IN:JAGSNPHARM69Neutral
IN:SAKAR68Neutral
IN:LINCOLN67Neutral
IN:INDSWFTLAB51Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 79Outperform | INR 20.74B | 24.26 | ― | 0.45% | 0.44% | 48.60% | |
| 74Outperform | INR 19.37B | 15.98 | ― | 0.69% | 20.22% | 73.03% | |
| 69Neutral | INR 13.99B | 30.72 | ― | 1.91% | 11.71% | -26.92% | |
| 68Neutral | INR 22.16B | 52.40 | ― | ― | 47.99% | 117.99% | |
| 67Neutral | INR 10.29B | 10.63 | ― | 0.35% | 14.25% | 21.11% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | INR 29.21B | 34.50 | ― | ― | 66.39% | -72.31% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:JAGSNPHARM | Jagsonpal Pharmaceuticals Ltd. | 209.70 | 11.82 | 5.97% | |
| IN:INDSWFTLAB | Ind-Swift Laboratories Ltd. | 330.20 | 229.50 | 227.90% | |
| IN:LINCOLN | Lincoln Pharmaceuticals Ltd | 511.90 | -16.05 | -3.04% | |
| IN:SAKAR | Sakar Healthcare Ltd | 976.20 | 603.80 | 162.14% | |
| IN:SYNCOMF | Syncom Formulation (India) Ltd. | 22.09 | 6.31 | 39.97% | |
| IN:VENUSREM | Venus Remedies Limited | 1500.75 | 802.65 | 114.98% |
Jagsonpal Pharmaceuticals Ltd. Corporate Events
Jagsonpal Pharma Sets Virtual AGM and Dividend Record Date for September 2026
Jagsonpal Pharmaceuticals Limited has scheduled its 47th Annual General Meeting for September 18, 2026, to be conducted via video conferencing and other audio-visual means in line with regulatory guidance. The company has circulated the AGM notice an...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
